Callisto

Callisto Pharmaceuticals Completes Enrollment of Phase II Trial of Atiprimod in Neuroendocrine Cancer

... NEW YORK, Sept. 20 /PRNewswire-FirstCall/ -- callisto Pharmaceuticals, Inc. (Amex: KAL; FWB: CA4), a dev... relapsed or refractory multiple myeloma patients. callisto earlier announced in June, 2006 interim data from ... abdominal pain and valvular heart disease. About callisto Pharmaceuticals, Inc. ...

Callisto Reports on Second-Quarter 2007 Milestones

...grams NEW YORK, Aug. 8 /PRNewswire-FirstCall/ -- callisto Pharmaceuticals, Inc. (Amex: KAL; FWB: CA4), a dev...g (synthetic molecule) of uroguanylin developed by callisto scientists, and is proprietary to Callisto. Guanil... being evaluated in animal models of GI disorders. callisto plans to initiate clinical trials of Guanilib in e...

Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients

... NEW YORK, Aug. 9 /PRNewswire-FirstCall/ -- callisto Pharmaceuticals, Inc. (Amex: KAL; FWB: CA4), a dev...erested in participating in this trial." Currently callisto has enrolled 31 patients of the 40 subjects planne... relapsed or refractory multiple myeloma patients. callisto earlier announced in June, 2006 interim data from ...

Callisto Intends to Move Guanilib into Clinical Trials in Ulcerative Colitis

...e drug is currently in preclinical development and callisto intends to move the drug into clinical trials in u...proprietary program that was developed in-house by callisto scientists and the company owns 100% of the worldw...ib in GI inflammatory diseases and colon cancer. callisto believes that Guanilib is presently the best physi...

Callisto Pharmaceuticals Announces Publication of Research Article on Atiprimod Preclinical Studies in Mantle Cell Lymphoma

..., S. Hong, F. Samaniego, J. Romaguera and Q. Yi. callisto is a biopharmaceutical company focused on the deve...cute leukemia, a currently incurable blood cancer. callisto initiated a clinical trial of L- Annamycin in pedi...compared to currently available drug alternatives. callisto also has drugs in preclinical development for gast...